RENOVARO INC (RENB)

US29350E1047 - Common Stock

0.6103  +0.09 (+18.07%)

After market: 0.585 -0.03 (-4.15%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

RENOVARO INC

NASDAQ:RENB (11/27/2024, 9:03:20 PM)

After market: 0.585 -0.03 (-4.15%)

0.6103

+0.09 (+18.07%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-59.04%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap96.87M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

RENB Daily chart

Company Profile

Renovaro, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. The company is headquartered in Los Angeles, California and currently employs 25 full-time employees. The company went IPO on 2014-11-18. The firm operates through two subsidiaries: Renovaro Biosciences, Inc. (Renovaro Biosciences) and Renovaro Cube. Renovaro Biosciences is a biotechnology company intending to develop advanced allogeneic cell and gene therapies to promote stronger immune system responses potentially for long-term or life-long cancer remission in some of the deadliest cancers, and potentially to treat or cure serious infectious diseases such as Human Immunodeficiency Virus (HIV) infections. Renovaro Cube is an AI-driven healthcare technology company focusing on the earliest possible detection of cancer and its recurrence. Renovaro Cube has developed an AI platform that analyzes genetics using Explainable AI to provide earlier and more accurate cancer diagnosis. This platform uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients.

Company Info

RENOVARO INC

Century City Medical Plaza, 2080 Century City East, Suite 906

Los Angeles CALIFORNIA

P: 14539179840

Employees: 25

Website: https://renovarobio.com/

RENB News

News Image24 days ago - Renovaro IncRenovaro Issues Shareholder Letter and Provides Corporate Update
News Image24 days ago - Renovaro IncRenovaro Issues Shareholder Letter and Provides Corporate Update

Renovaro Issues Shareholder Letter and Provides Corporate Update...

News Imagea month ago - Renovaro IncRenovaroCube Presents Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore Sequencing
News Imagea month ago - Renovaro IncRenovaroCube Presents Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore Sequencing

AMSTERDAM, Oct. 17, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) – RenovaroCube, a leader in AI-driven cancer diagnostics by integrating multi-omics with...

News Imagea month ago - Get NewsPowerful Leadership Transition to Optimize Highly Promising AI Platform, RenovaroCube for Multi-Cancer Early Detection and Patient Monitoring: Renovaro, Inc. (Nasdaq: RENB)
News Imagea month ago - Renovaro IncRenovaro Announces Strategic Restructuring and Leadership Transition

RENB Twits

Here you can normally see the latest stock twits on RENB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example